publication date: Feb. 9, 2018
Clinical Roundup In phase III study Tecentriq and Avastin reduced risk of disease worsening/death by 26 percent in advanced kidney cancer
Genentech announced results from the positive phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
The study met its co-primary endpoint of investigator-assessed progression-free survival in people whose disease expressed the PD-L1 (expression ≥ 1 percent) protein. Those who received Tecentriq plus Avastin had a 26-percent reduced risk of disease worsening or death compared to people treated with sunitinib (median PFS [mPFS]: 11.2 vs. 7.7 months; HR=0.74; 95 percent CI 0.57, 0.96; p=0.02).
Initial observations from the co-primary endpoint of overall survival in the overall study population (intention-to-treat) are still immature. Safety for the Tecentriq and Avastin combination appeared consistent with the known safety profile of the individual medicines and what was previously reported in the phase II IMmotion150 study.
No new safety signals were identified with the combination. The rate of treatment-related grade III-IV adverse events was lower with the Tecentriq and Avastin combination (40 percent) than with sunitinib alone (54 percent) in all treated patients.
Observations of a pre-specified subgroup analysis of the Tecentriq and Avastin combination indicated that, in people whose disease expressed PD-L1, a numerical difference in PFS favoring Tecentriq was seen across all patient risk factor groups (favorable, intermediate and … Continue reading In phase III study Tecentriq and Avastin reduced risk of disease worsening/death by 26 percent in advanced kidney cancer
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.